Theseus Pharmaceuticals, Inc. stock is up 78.3% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 7 December’s closed higher than November.
Theseus Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of targeted therapies for cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.